A Phase 1-2 Study of ARV-806 in People With Advanced Solid Tumors

Full Title

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Purpose

Researchers want to find the best dose of ARV-806 to use in people with advanced solid tumor cancers. The people in this study have solid tumors that cannot be cured with standard therapies. In addition, the tumors have a mutation (change) in the KRAS, gene, called KRAS G12D, which can make cancer cells grow.

ARV-806 is designed to help get rid of bad or unwanted proteins. It breaks down the KRAS protein in cancer cells, which plays a role in cancer growth and survival. By targeting this protein, ARV-806 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have an advanced solid tumor that keeps growing after treatment or for which there is no standard therapy.
• Have a tumor with a KRAS G12D mutation.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call 646-888-4226.